Rewriting the Narrative on the Oncology Care Model

This editorial responds to the final evaluation of the Oncology Care Model, the first cancer-specific alternative payment model from the Centers for Medicare and Medicaid Services, which found a relative reduction of $616 per episode in total spending. The authors argue that the conventional framing of the OCM as a failed experiment misses the broader and more instructive story, contending that the model's structural design, rather than the concept of value-based oncology care itself, was the primary driver of its limitations. They call for a more nuanced interpretation of the evidence that informs how next-generation alternative payment models in oncology are designed and evaluated.

The commentary reflects a broader and increasingly urgent debate about how to align financial incentives in cancer care with the dual goals of improving patient outcomes and controlling costs. As CMS develops successor models, the authors' argument that design flaws rather than fundamental failures should shape the lessons drawn from the OCM carries significant implications for policy, practice, and the future of value-based care in oncology.